Drug Profile
HGP 0918
Alternative Names: HGP0918Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO)
- 01 Jun 2016 Hanmi Pharmaceuticals initiates enrolment in a phase I trial in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT02941796)
- 01 Jul 2015 Phase-I clinical trials in Hyperlipidaemia (In volunteers) in South Korea (PO) (NCT02554136)